Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Anticoagulation in atrial fibrillation.

Steinberg BA, Piccini JP.

BMJ. 2014 Apr 14;348:g2116. doi: 10.1136/bmj.g2116. Review.

2.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

3.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
4.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
5.

Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.

Kosar L, Jin M, Kamrul R, Schuster B.

Can Fam Physician. 2012 Aug;58(8):850-8. Review. No abstract available.

6.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
7.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
8.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
9.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
10.

Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.

Ogbonna KC, Jeffery SM.

Drugs Aging. 2013 Jul;30(7):513-25. doi: 10.1007/s40266-013-0075-y. Review.

PMID:
23591934
11.

A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.

Kasmeridis C, Lip GY, Apostolakis S.

Hosp Pract (1995). 2013 Feb;41(1):61-70. doi: 10.3810/hp.2013.02.1011. Review.

PMID:
23466968
12.

{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.

[No authors listed]

Drug Ther Bull. 2014 Jan;52(1):6-9. doi: 10.1136/dtb.2014.1.0228. Epub 2014 Jan 8. Review.

PMID:
24401533
13.

Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.

Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.

Clin Ther. 2013 Jul;35(7):967-984.e2. doi: 10.1016/j.clinthera.2013.05.011.

PMID:
23870607
14.

Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.

Lenchus JD.

Hosp Pract (1995). 2013 Feb;41(1):49-60. doi: 10.3810/hp.2013.02.1007.

PMID:
23466967
15.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

16.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
17.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
18.

New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.

Bhimani AA, Hong M.

Rev Recent Clin Trials. 2013 Jun;8(2):78-85. Review.

PMID:
23859143
19.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498
20.

Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.

Lane DA, Wood K.

Circulation. 2015 Apr 21;131(16):e412-5. doi: 10.1161/CIRCULATIONAHA.114.012808. No abstract available.

Supplemental Content

Support Center